Sifting through countless of stocks in the Biotechnology industry can be tedious, and sometimes two stocks are just too similar to judge which is the better investment. If you’re on the fence about investing in Protagonist Therapeutics, Inc., Vir Biotechnology or Inc. because you’re not sure how they measure up, it’s important to compare them on a few factors before making your decision.

Read on to learn how Protagonist Therapeutics, Inc., Vir Biotechnology and Inc. compare based on key financial metrics to determine which better meets your investment needs.

About Protagonist Therapeutics, Inc., Vir Biotechnology and Inc.

Protagonist Therapeutics, Inc. operates as a discovery and development company in the United States. It develops Icotyde, a first-in-class investigational targeted oral peptide for the treatment of adults and pediatric patients 12 years of age and older with moderate-to-severe plaque psoriasis; and Rusfertide, a first-in-class investigational injectable mimetic of the natural hormone hepcidin in Phase 3 development for the treatment of the rare blood disorder polycythemia vera. The company is also developing PN-881, a potential best-in-class oral peptide IL-17 antagonist, for the treatment of immune-mediated skin diseases in Phase 1 clinical trials; PN-477 and PN-458, which are development candidates for the treatment of obesity; PN-8047, an orally administered hepcidin functional mimetic small molecule; L-4R alpha antagonist for the treatment of atopic dermatitis and moderate-to-severe asthma; and amylinR-based oral and subcutaneous mono- and poly-agonists for the treatment of obesity. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.

Vir Biotechnology, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutic products to treat and prevent serious infectious diseases in the United States and internationally. Its clinical development pipeline consists of product investigational therapies targeting hepatitis delta virus (HDV) and other solid tumors. The company’s preclinical candidates include those targeting influenza A and B antibodies and antibody drug conjugates, and coronavirus monoclonal antibodies; and PRO-XTEN, a dual-masked TCEs targeting variety of solid tumors. It has grant collaboration and license agreement with Astellas; license agreement with Norgine for the treatment of CHD; amended and restated letter agreement with the Gates Foundation; an option and license agreement with Brii Biosciences Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreement with the Institute for Research in Biomedicine; a license agreement with The Rockefeller University; license agreements with Xencor; and a collaborative research agreement with GlaxoSmithKline Biologicals S.A. Vir Biotechnology, Inc. was incorporated in 2016 and is headquartered in San Francisco, California.

Latest Biotechnology and Protagonist Therapeutics, Inc., Vir Biotechnology, Inc. Stock News

As of October 30, 2026, Protagonist Therapeutics, Inc. had a $9.4 billion market capitalization, compared to the Biotechnology median of $226.9 million. Protagonist Therapeutics, Inc.’s stock is up 65.8% in 2026, up 4.6% in the previous five trading days and up 89.02% in the past year.

Currently, Protagonist Therapeutics, Inc.’s price-earnings ratio is 118.7. Protagonist Therapeutics, Inc.’s trailing 12-month revenue is $282.0 million with a 29.4% net profit margin. As of October 30, 2026, Protagonist Therapeutics, Inc. has not reported significant year-over-year quarterly sales. Analysts expect adjusted earnings to reach $4.767 per share for the current fiscal year. Protagonist Therapeutics, Inc. does not currently pay a dividend.

As of October 30, 2026, Vir Biotechnology, Inc. had a $1.9 billion market cap, putting it in the 54th percentile of all stocks. Vir Biotechnology, Inc.’s stock is up 87.4% in 2026, up 6.9% in the previous five trading days and up 91.12% in the past year.

Currently, Vir Biotechnology, Inc. does not have a price-earnings ratio. Vir Biotechnology, Inc.’s trailing 12-month revenue is $303.2 million with a -83.0% net profit margin. As of October 30, 2026, Vir Biotechnology, Inc. has not reported significant year-over-year quarterly sales. Analysts expect adjusted earnings to reach $-1.755 per share for the current fiscal year. Vir Biotechnology, Inc. does not currently pay a dividend.

How We Compare Protagonist Therapeutics, Inc., Vir Biotechnology and Inc. Stock Grades

Stock evaluation requires access to huge amounts of data and the knowledge and time to sift through it all, make sense of financial ratios, read income statements and analyze recent stock movements. AAII created A+ Investor, a robust data suite that condenses data research in an actionable and customizable way suitable for investors of all knowledge levels, to help investors streamline and work through such data.

AAII’s proprietary stock grades come with A+ Investor. These offer intuitive A‐F grades for each of five key investing factors: value, growth, momentum, earnings estimate revisions and quality. Here, we’ll take a closer look at Protagonist Therapeutics, Inc., Vir Biotechnology and Inc.’s stock grades to see how they measure up against one another.

Learn more about A+ Investor here!

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

Protagonist Therapeutics, Inc., Vir Biotechnology and Inc. Growth Grades

Company	Ticker	Growth
Protagonist Therapeutics, Inc.	PTGX	D
Vir Biotechnology, Inc.	VIR	F

The foundation of growth investing is seeking out stocks of companies exhibiting strong, consistent and prolonged growth that is expected to continue into the future.

In order to compute the growth score and assign it a letter grade, the percentile ranks for each of three components‐consistency of annual sales growth, five-year sales growth rankings adjusted for extreme levels, and consistency of positive annual cash from operations‐must be determined. These three rank figures are added together, and the sum is ranked against the entire stock universe to arrive at a company’s Growth Score to create an equal distribution of grades.

The companies in the bottom 20% of the stock universe receive Growth Grades of F, considered to be very weak, while those in the top 20% receive A grades, which are considered very strong.

Protagonist Therapeutics, Inc. has a Growth Score of 29, which is Weak. Vir Biotechnology, Inc. has a Growth Score of 4, which is Very Weak.

The Growth Stock Winner: No Clear Winner

Neither Protagonist Therapeutics, Inc., Vir Biotechnology or Inc. has a high enough Growth Grade to be considered a “winner.” Investors who are considering these companies should do additional due diligence and research to see if either could be a good addition to their portfolios. It’s important to look at a wide range of financial metrics in order to determine if Protagonist Therapeutics, Inc., Vir Biotechnology or Inc. is the better investment when it comes to sustainable growth.

Protagonist Therapeutics, Inc., Vir Biotechnology and Inc.’s Quality Grades

Company	Ticker	Quality
Protagonist Therapeutics, Inc.	PTGX	A
Vir Biotechnology, Inc.	VIR	D

Like the Value Grade, AAII’s A+ Investor Quality Grade comes from the percentile rank of key metrics. Specifically, the Quality Score is the percentile rank of the average of the percentile ranks of return on assets (ROA), return on invested capital (ROIC), gross profit relative to assets, buyback yield, change in total liabilities to assets, accruals, Z double prime bankruptcy risk (Z) score and the F-Score.

The score is variable, meaning it can consider all eight measures or, should any of the eight measures not be valid, the remaining measures that are valid. To be assigned a Quality Score, stocks must have a valid (non-null) measure and corresponding ranking for at least four of the eight quality measures.

The Quality Score is used to assess the underlying “quality” of a particular stock. A higher-quality stock possesses traits associated with upside potential and reduced downside risk. Backtesting of the Quality Grade shows that stocks with higher grades, on average, outperformed stocks with lower grades over the period of 1998 through 2019.

Stocks receive better grades (higher scores) for having higher scores for the quality subcomponents and worse grades (lower scores) for lower scores for the subcomponents.

Protagonist Therapeutics, Inc. has a Quality Score of 88, which is Very Strong. Vir Biotechnology, Inc. has a Quality Score of 22, which is Weak.

The Quality Grade Winner: Protagonist Therapeutics, Inc.

As you can clearly see from the Quality Grade breakdown above, Protagonist Therapeutics, Inc. has a better overall quality grade than Vir Biotechnology, Inc.. For investors who are looking for companies with higher quality than others in the same industry, Protagonist Therapeutics, Inc. could be a good stock to add to their portfolios. However, it’s important for investors to analyze multiple factors based on a wide range of metrics before deciding whether to buy.

Protagonist Therapeutics, Inc., Vir Biotechnology and Inc.’s Estimate Revisions Grades

Company	Ticker	Earnings Estimate
Protagonist Therapeutics, Inc.	PTGX	C
Vir Biotechnology, Inc.	VIR	F

Earnings estimate revisions scores consider the magnitude of a company’s earnings surprise in its last two reported fiscal quarters. Often, positive surprises beget further positive surprises‐or at least continued sales growth (the exact opposite is generally true, too).

Estimate revisions offer an indication of what analysts are thinking about the short-term prospects of a firm. Estimate revisions are based on the statistical significance of a firm’s last two quarterly earnings surprises and the percentage change in its consensus estimate for the current fiscal year over the past month and past three months.

Protagonist Therapeutics, Inc. has a Earnings Estimate Score of 48, which is Neutral. Vir Biotechnology, Inc. has a Earnings Estimate Score of 16, which is Very Negative.

The Earnings Estimate Revisions Stock Winner: No Clear Winner

Neither Protagonist Therapeutics, Inc., Vir Biotechnology or Inc. has an Earnings Estimate Revisions Grade that could be considered a “winner.” Investors considering these companies should do additional due diligence and research to see if either could be a good addition to their portfolios. It’s important to look at a wide range of financial metrics in order to determine if Protagonist Therapeutics, Inc., Vir Biotechnology or Inc. is the better investment when it comes to estimate revisions.

Other Protagonist Therapeutics, Inc., Vir Biotechnology and Inc. Grades

In addition to Estimate Revisions, Growth and Quality, A+ Investor also provides grades for Value and Momentum.

Momentum grades help uncover stocks experiencing anomalously high rates of return; research finds that stocks with high relative levels of momentum tend to outperform, whereas those with low levels of momentum tend to continue underperforming.

Successful stock investing involves buying low and selling high, so stock valuation is an important consideration for stock selection. Buying stocks that are going to go up typically means buying stocks that are undervalued in the first place, although momentum investors may argue that point.

These 2 key factors, when combined with the above, provide a holistic view into a particular stock. Further, by joining A+ Investor you can see whether Protagonist Therapeutics, Inc., Vir Biotechnology and Inc. pass any of our 60+ stock screens that have outperformed the market since their creation.

So, Which Is the Better Investment, Protagonist Therapeutics, Inc., Vir Biotechnology or Inc. Stock?

Overall, Protagonist Therapeutics, Inc. stock has a Growth Score of 29, Estimate Revisions Score of 48 and Quality Score of 88.

Vir Biotechnology, Inc. stock has a Growth Score of 4, Estimate Revisions Score of 16 and Quality Score of 22.

Comparing Protagonist Therapeutics, Inc., Vir Biotechnology and Inc.’s grades, scores and metrics can act as a solid basis to determine whether they may be a good investment or not. You’ll also want to look at your portfolio’s asset allocation as well as your risk tolerance and financial goals to see if either of these stocks would make a good fit for you. AAII can help you figure out which investments align with your individual needs and preferences.

Investors are encouraged to do their own due diligence and research. In this way, individuals can effectively become managers of their own assets‐without having to rely on others for financial independence. You can count on AAII for timeless articles on financial planning and stock-picking, unbiased research and actionable analysis.

A+ Investor adds to our qualitative teaching with a powerful data suite to help you whittle down investment choices to find stocks, exchange-traded funds (ETFs) or mutual funds that meet your needs.

AAII Disclaimer

We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown, because past, hypothetical or simulated performance is not necessarily indicative of future results. Before making an investment decision, you should consider your circumstances and whether the information on our content is applicable to your situation. This information was prepared in good faith, and we accept no liability for any errors or omissions. The full disclaimer can be read here.